GLP-1s May Be Working in an Entirely Different Way Than We Thought
How can this be?
Popular weight-loss medications like Ozempic and Wegovy may operate through mechanisms far more intricate than previously believed. While these semaglutide-based drugs are known to reduce appetite, emerging research suggests their long-term effectiveness involves additional biological pathways beyond simple hunger suppression.
In a recent study published in PNAS, Yale researchers discovered that brain cells responsible for hunger signaling may play a crucial role in sustaining semaglutide’s weight-loss benefits. When these cells, called AgRP neurons, were disabled in female mice, the animals continued eating less during treatment but failed to maintain their weight loss, regaining lost weight within two weeks. In contrast, mice with fully functional AgRP neurons sustained their weight reduction, indicating that appetite suppression alone cannot explain the drug’s complete effectiveness.
The findings reveal that AgRP neurons coordinate broader metabolic responses beyond hunger regulation, including how the body mobilizes and utilizes stored fat. This suggests semaglutide’s success depends on the proper functioning of these cells to maintain healthy energy mobilization from fat tissue. However, researchers emphasize significant limitations: the experiments involved only female mice, and results differed in males under tested conditions.
Scientists stress these findings remain preliminary and should not influence how people currently use GLP-1 medications. Further research in humans is necessary to determine whether similar mechanisms exist in people and could eventually explain why individuals respond differently to these drugs.
Originally reported by Sciencealert →
About the Author
